Madrigal Pharmaceuticals, Inc. MDGL
432.79 USD +33.16 (+8.30%)
At closeNov 9, 2026, 4:00 PM EST
432.79 0.00 0.00%
After hours · Nov 9, 4:00 PM ET
402.00 Day range 438.74
353.54 52-week range 615.00
- YTD
- -25.68%
- 1 year
- -11.54%
- Market cap
- 10.05B
- Revenue (ttm)
- 1.43B
- Profit margin
- -10.89%
- EPS (ttm)
- -6.34
- Shares out
- 23.23M
- Forward P/E
- 38.61
- YTD return
- -25.68%
- 1-year return
- -11.54%
- Volume
- 571.31K
- Avg volume
- 345.52K
- Open
- 412.08
- Previous close
- 399.63
- Day's range
- 402.00 – 438.74
- 52-week range
- 353.54 – 615.00
- Beta
- -1.00
- Analysts
- Strong Buy
- Price target
- 688.94 (+59.2%)
- Earnings date
- Feb 18, 2027
5D -32.54 (-7.07%)
Key statistics
- Enterprise value
- 8.68B
- PEG ratio
- 0.00
- Price / sales
- 7.04
- Price / book
- 16.03
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 50.10%
- Free cash flow
- -112.43M
- Total cash
- 960.97M
- Total debt
- 354.22M
- Return on equity
- -24.82%
- Short % of float
- 11.10%
- 50-day average
- 486.74
- 200-day average
- 497.60
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 688.94 +59.2% upside
Now 432.79
- Target (low)
- 479.00
- Target (mean)
- 688.94
- Target (high)
- 962.00
Ratings (0m) 19 18 buy · 1 hold · 0 sell
- Strong buy3
- Buy15
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 18, 2027
Expected Feb 18, 2027. Consensus EPS estimate 1.92.
Financials — quick view
MDGL Revenue — quarterly 431.27M
MDGL Net income — quarterly 55.44M
MDGL EPS — quarterly 1.90
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 18, 2027 | Dec 30, 2026 | 1.40 | — | — | — |
| Nov 3, 2026 | Sep 30, 2026 | -0.86315 | 1.83 | +2.69 | +312.01% |
| Jul 30, 2026 | Jun 30, 2026 | -2.68 | -1.99 | +0.69 | +25.75% |
| May 6, 2026 | Mar 31, 2026 | -3.61 | -3.25 | +0.36 | +9.97% |
| Feb 19, 2026 | Dec 31, 2025 | 0.04 | -2.57 | -2.61 | -6,525.00% |
| Nov 4, 2025 | Sep 30, 2025 | -2.04 | -5.08 | -3.04 | -149.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | Canaccord Genuity | main | Buy | Buy |
| Nov 4, 2026 | Truist Securities | reit | Buy | Buy |
| Nov 3, 2026 | Citigroup | main | Buy | Buy |
| Sep 23, 2026 | Citigroup | init | — | Buy |
| Aug 4, 2026 | Wolfe Research | up | Peer Perform | Outperform |
| Aug 3, 2026 | Barclays | main | Overweight | Overweight |
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- madrigalpharma.com
News
Kaplan Fox Announces a Securities Investigation into Madrigal Pharmaceuticals, Inc. (MDGL) - Investors Encouraged to Contact the Firm 
MDGL Investors Have Opportunity to Join Madrigal Pharmaceuticals, Inc. Fraud Investigation with SBS Law 
MDGL Investigation Reminder: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP 
Notice of Investigation of MDGL: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP 
Kaplan Fox & Kilsheimer LLP Encourages Madrigal Pharmaceuticals, Inc. (MDGL) Investors to Contact the Firm Regarding Potential Securities Law Violations 
Madrigal Pharmaceuticals Announces Data From Its Rezdiffra Trials Demonstrated 55% Participants Achieved Over 25% Improvement In Liver Stiffness, 48% Patients Reports Over 30% Improvement At 12 Months 
Madrigal Announces New Real-World Data at AASLD 2026 Demonstrating Improvements in Liver Stiffness and Cardiometabolic Health Markers with Rezdiffra 
Top 3 Health Care Stocks You'll Regret Missing In Q4 
Reviewing Madrigal Pharmaceuticals (NASDAQ:MDGL) & OSR (NASDAQ:OSRH) 
Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $633
Your note
Sign in to keep a note on MDGL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS, L.P. | Unknown | Stock Award(Grant) | Jun 16, 2026 | 0 |
| CRAVES FREDERICK B | Director | Sale | Mar 12, 2025 | 383,547 |
| DIER MARDI C | Chief Financial Officer | Sale | Mar 5, 2026 | 12,490 |
| FRIEDMAN PAUL A | Director | Sale | Jan 8, 2026 | 842,704 |
| HUNTSMAN CAROLE A | Officer | Sale | Mar 5, 2026 | 12,692 |
| KELLEY SHANNON T | General Counsel | Sale | Aug 16, 2026 | 11,474 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 9.23% | 2,143,131 | 927.53M | Jun 29, 2026 |
| RTW Investments LP | 8.58% | 1,993,687 | 862.85M | Jun 29, 2026 |
| Jupiter Topco LLC | 8.33% | 1,936,099 | 837.92M | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 7.89% | 1,833,333 | 793.45M | Jun 29, 2026 |
| PAULSON & CO. INC. | 5.77% | 1,340,020 | 579.95M | Jun 29, 2026 |
| Blackrock Inc. | 5.17% | 1,200,770 | 519.68M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.52% | 584,997 | 253.18M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.42% | 563,117 | 243.71M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.82% | 423,142 | 183.13M | Jun 29, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Forty Fund | 1.46% | 338,602 | 146.54M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.16% | 270,288 | 116.98M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.05% | 243,683 | 105.46M | Jun 29, 2026 |